Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06520878

Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment

Impact of NANO-PSO (omega 5) Supplementation on Cognitive Abilities of Older Adults with Mild to Moderate Non-vascular Cognitive Impairment

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Distribuidora Biolife SA de CV · Industry
Sex
All
Age
60 Years
Healthy volunteers
Not accepted

Summary

The objective of this randomized, triple-blind, placebo-controlled clinical trial is to compare NANO-PSO therapy against placebo in improving cognitive abilities in older adults with mild to moderate non-vascular cognitive impairment over six months of treatment. The primary questions it aims to answer are: • Does NANO-PSO therapy improve cognitive abilities in older adults with mild to moderate non-vascular cognitive impairment over six months of treatment compared to placebo? The researchers will compare NANO-PSO therapy against placebo to see if it benefits the cognitive abilities of geriatric patients. Participants will be required to: * Consume two capsules of NANO-PSO or placebo daily in the morning for six months. * Be evaluated monthly by phone to identify potential risks and ensure adherence to the treatment. * Be evaluated in person at 90 and 180 days of treatment. * The patient or primary caregiver must maintain a log to confirm daily dose consumption and will have a direct communication line with the attending physicians in case of questions about ingestion or possible adverse reactions. * At the end of the final patient evaluation, a quality questionnaire will be administered.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTNANO-PSO (pomegranate seed oil)NANO-PSO administered orally, 2 capsules, equivalent to 640 mg of pomegranate seed oil, every 24 hours in the morning with food.
DIETARY_SUPPLEMENTPlaceboPlacebo administered orally, 2 capsules, equivalent to 640 mg of mineral oil, every 24 hours in the morning with food.

Timeline

Start date
2025-02-12
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2024-07-25
Last updated
2025-02-06

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT06520878. Inclusion in this directory is not an endorsement.

Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment (NCT06520878) · Clinical Trials Directory